HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia

Leukemia

Volumn 22, Issue 7, 2008, Pages 1387-1394

  Rutten, C E ^a   van Luxemburg Heijs, S A P ^a   Griffioen, M ^a   Marijt, E W A ^a   Jedema, I ^a   Heemskerk, M H M ^a   Posthuma, E F M ^a   Willemze, R ^a   Falkenburg, J H F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DPB1 ANTIGEN; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; BONE MARROW CELL; CANCER CELL; CANCER IMMUNOTHERAPY; CASE REPORT; CD4+ T LYMPHOCYTE; CELL ISOLATION; CYTOLYSIS; DONOR LYMPHOCYTE INFUSION; ENGRAFTMENT; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKEMIC LYMPHOPLASMACYTIC LYMPHOMA; LYMPHOID CELL; MULTIPLE CYCLE TREATMENT; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RETROVIRUS; STEM CELL MOBILIZATION; T CELL DEPLETION;

CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTOCOMPATIBILITY TESTING; HLA-DP ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED;

EID: 47549117743     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.90     Document Type: Article

References (37)

1. Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1986; 1: 53-66.
2. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
3. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
4. Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003; 17: 153-162.
5. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51 443-447.
6. de Bueger M, Bakker A, van Rood JJ, Van der WF, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149: 1788-1794.
7. Falkenburg JH, van de Corput L, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 2003; 31: 743-751.
8. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: 2742-2747.
9. Vogt MH, van den Muijsenberg JW, Goulmy E, Spierings E, Kluck P, Kester MG et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002; 99: 3027-3032.
10. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993; 11: 385-402.
11. Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol 1984; 83: 88-90.
12. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA 1984; 81: 4917-4921.
13. Ferrara JL. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993; 5: 794-799.
14. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583.
15. Loiseau P, Esperou H, Busson M, Sghiri R, Tamouza R, Hilarius M et al DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation. Bone Marrow Transplant 2002; 30: 497-502.
16. Moreau P, Cesbron A. HLA-DP and allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 13: 675-681.
17. Petersdorf EW, Smith AG, Mickelson EM, Longton GM, Anasetti C, Choo SY et al. The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. Blood 1993; 81: 1923-1932.
18. Petersdorf EW, Gooley T, Malkki M, Anasetti C, Martin P, Woolfrey A et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol 2001; 112 988-994.
19. Varney MD, Lester S, McCluskey J, Gao X, Tait BD. Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation. Hum Immunol 1999; 60: 532-538.
20. Ringden O, Schaffer M, Le Blanc K, Persson U, Hauzenberger D, Abedi MR et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers? Biol Blood Marrow Transplant 2004; 10: 128-134.
21. Shaw BE, Marsh SG, Mayor NP, Russell NH, Madrigal JA. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood 2006; 107: 1220-1226.
22. Barge RM, Osanto S, Marijt WA, Starrenburg CW, Fibbe WE, Nortier JW et al. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol 2003; 31: 865-872.
23. Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA, Barbui AM, van Egmond HM, Strijbosch MP et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 2004; 18: 798-808.
24. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004; 103: 2677-2682.
25. Heemskerk MH, Hoogeboom M, de Paus RA, Kester MG, van der Hoorn MA, Goulmy E et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003; 102: 3530-3540.
26. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421: 852-856.
27. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300: 337-339.
28. Dodi IA, Van Rhee F, Forde HC, Roura-Mir C, Jaraquemada D, Goldman JM et al. CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy 2002; 4: 353-363.
29. Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA, van Egmond HM, Barbui AM, Strijbosch MP et al. Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNgamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia 2005; 19: 83-90.
30. Matsushita M, Yamazaki R, Ikeda H, Mori T, Sumimoto H, Fujita T et al Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. Br J Haematol 2006; 132: 56-65.
31. Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-1208.
32. Gonwa TA, Peterlin BM, Stobo JD. Human-Ir genes: Structure and function. Adv Immunol 1983; 34: 71-96.
33. Ibisch C, Gallot G, Vivien R, Diez E, Jotereau F, Garand R et al. Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: A perspective for adjuvant immunotherapy post-bone marrow transplantation. Bone Marrow Transplant 1999; 23: 1153-1159.
34. Nicholson I, Varney M, Kanaan C, Grigg A, Szer J, Tiedemann K et al Alloresponses to HLA-DP detected in the primary MLR: Correlation with a single amino acid difference. Hum Immunol 1997; 55: 163-169.
35. Zino E, Frumento G, Marktel S, Sormani MP, Ficara F, Di Terlizzi S et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood 2004; 103: 1417-1424.
36. Cesbron A, Moreau P, Cheneau ML, Cury S, Milpied N, Muller JY et al Crucial role of the third and fourth hypervariable regions of HLA-DPB1 allelic sequences in primary mixed-lymphocyte reaction: application in allogeneic bone marrow transplantation. Transplant Proc 1993; 25 (1 Part 2): 1232-1233.
37. Naruse TK, Nose Y, Kagiya M, Liao G, Nabeya N, Kimura M et al. Cloned primed lymphocyte test cells recognize the fourth, fifth, and sixth hypervariable regions at amino acid positions 65-87 of the DPB1 molecule. Hum Immunol 1995; 42: 123-130.